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ABSTRACT 
Rapid advances in synthetic biology are driving the development of genetically engineered microbes as therapeutic agents for a multitude 
of human diseases, including cancer. In particular, the immunosuppressive microenvironment of solid tumors creates a favorable niche 
for systemically administered bacteria to engraft in the tumor and release therapeutic payloads. However, such payloads can be harmful 
if released in healthy tissues where the bacteria also engraft in smaller numbers. To address this limitation, we engineer therapeutic 
bacteria to be controlled by focused ultrasound, a form of energy that can be applied noninvasively to specific anatomical sites such as 
solid tumors. This control is provided by a temperature-actuated genetic state switch that produces lasting therapeutic output in response 
to briefly applied focused ultrasound hyperthermia. Using a combination of rational design and high-throughput screening we optimized 
the switching circuits of engineered cells and connected their activity to the release of immune checkpoint inhibitors. In a clinically 
relevant cancer model, ultrasound-activated therapeutic microbes successfully turned on in situ and induced a marked suppression of 
tumor growth. This technology provides a critical tool for the spatiotemporal targeting of potent bacterial therapeutics in a variety of 
biological and clinical scenarios. 
 
INTRODUCTION 
Cell therapies are rapidly emerging as an exciting and effective 
class of technologies for cancer treatment1–3. Among the cell types 
being investigated for therapy, immune cells have excelled in the 
treatment of hematologic malignancies. However, their use in 
solid tumors has been hampered by their reduced ability to 
penetrate and function in the tumor’s  immunosuppressive 
environment, especially within immune-privileged hypoxic cores4–
6. Conversely, the reduced immune activity of some tumor cores 
creates a favorable microenvironment for the growth of certain 
bacteria, which can reach the tumors after systemic 
administration7–9. Capitalizing on their tumor-infiltrating 
properties, such bacteria can be engineered to function as effective 
cellular therapies by secreting therapeutic payloads to directly kill 
tumor cells or remodel the microenvironment to stimulate anti-
tumor immunity10–15. However, the benefits of microbial therapy 
are often counterbalanced by safety concerns accompanying the 
systemic injection of microbes into patients with limited control 
over their biodistribution or activity1,16,17. This is especially 
important given the well-documented engraftment of circulating 
bacteria into healthy tissues such as the liver, spleen, and certain 
hypoxic stem cell niches18–21. To avoid damaging healthy organs, 
it is crucial that the therapeutic activity of microbes be targeted to 
tumors.  
 Among the available mechanisms to regulate microbial 
function, systemically administered chemical inducers22,23 are 
incapable of targeting a particular anatomical site. Meanwhile, 
light-induced control elements provide high spatiotemporal 
precision24–26, but are constrained by the poor penetration of light 
into intact tissues27. In contrast, temperature-based control 
elements provide a combination of spatiotemporal control and 
depth, since temperature can be elevated precisely in deep tissues 
using noninvasive methods such as focused ultrasound (FUS)28–30.  
Indeed, it was recently demonstrated that FUS can be 
used in conjunction with temperature-dependent transcription 
factors to control the expression of bacterial genes31. However, 
these transcription factors operated in therapeutically irrelevant 
cloning strains of bacteria, had non-therapeutic outputs, and 
produced only transient activation unsuitable for tumor treatment, 
which typically requires weeks of therapeutic activity10,11,22. 
Here we describe the development of FUS-activated 
therapeutic bacteria in which a brief thermal stimulus activates 
sustained release of anti-cancer immunotherapy. We engineer 
these cellular agents by adapting temperature-sensitive 
transcription factors to the tumor-homing probiotic species E. coli 
Nissle 1917 and designing gene circuits in which they control an 
integrase-based state switch31,32 resulting in long-term therapy 
production. To improve the safety and efficacy of these cells, we 
screen random and rationally designed libraries of gene circuit 
variants for constructs with minimal baseline activity and maximal 
induction upon thermal stimulation. We use the optimized gene 
circuits to express immune checkpoint inhibitors targeting CTLA-
4 and PD-L1. In a mouse cancer model, we show that the resulting 
engineered microbes are reliably and chronically activated by a 
brief, noninvasive FUS treatment after systemic administration to 




Characterizing thermally responsive repressors in a 
therapeutically relevant microbe. To develop a 
temperature-actuated therapeutic circuit, we started with high-
performance temperature-dependent transcriptional repressors, 
which actuate transient gene expression in response to small 
changes in temperature around 37 ºC31. Since genetic elements 
tend to behave differently across cell types due to variations in 
protein expression and other aspects of the intracellular 
environment33, we first characterized the performance of these 
repressors in our chosen therapeutic chassis: E. coli Nissle 1917 
(EcN). This bacterial strain is approved for human probiotic use 
and is commonly employed in microbial tumor therapies10,34. We 
selected three repressor candidates—TlpA39, wild-type TcI, and 
TcI42—as our starting points due to their desirable activation 
temperature thresholds of 39 °C, 38 °C, and 42 °C, respectively
 To evaluate the performance of these candidates we 
designed reporter constructs where they regulate the expression of 
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a green fluorescent protein (GFP) (Fig. 1a), transformed them into 
EcN cells, and measured the corresponding cell density-
normalized fluorescence intensity as a function of temperature 
between 33 °C and 42 °C (Fig. 1b). As we were interested in using 
these bioswitches in vivo, we focused on the fold-change between 
the mammalian physiological temperature (37 °C) and an elevated 
temperature that can be used to trigger activation in vivo while 
minimizing thermal damage to local tissues (42 °C) (Fig. 1c). 
Results from these experiments indicated that TcI42 is the best 
candidate for integration into our thermal switch since it exhibits 
strong induction at 42 °C while maintaining low levels of baseline 
activity. 
 With TcI42 serving as the thermal transducer in our cells, 
we next sought to determine the minimal heating duration and 
ideal heating parameters required to achieve strong activation 
while minimizing damage to cells. We stimulated cells carrying the 
 
 
Figure 1 | Evaluating temperature-sensitive transcriptional repressors in E. coli Nissle 1917. (a) Illustration of the genetic circuit used 
to characterize the behavior of temperature-sensitive repressors in E. coli Nissle 1917. (b) Optical density (OD600)-normalized fluorescence as a function 
of induction temperature for a fixed duration of 1 hour, measured 24 hours after induction. (c) OD-normalized fluorescence 24 hours after a 1-hour 
induction at 37 °C or 42 °C for the constructs shown in b. Numbers indicate fold-change. (d) OD-normalized fluorescence as a function of induction 
duration. Cells were stimulated at 42 °C and fluorescence measured 24 hours later. (e) Illustration of the pulsatile heating scheme used to optimize 
thermal induction and cell viability. (f) OD-normalized fluorescence as a function of pulse duration for the TcI42 circuit. All samples were stimulated 
for a total of 1 hour at 42 °C and 1 hour at 37 °C and evaluated 24 hours later. Viable cell counts at various pulse durations plotted to reflect cell 
viability. Where not seen, error bars (±SEM) are smaller than the symbol. N=4 biological replicates for each sample. 
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circuit described in Fig. 1a by elevating the temperature to 42 °C 
for different durations and measured the corresponding 
fluorescence intensity (Fig. 1d). The results indicated that a 
minimal heating time of one hour is needed for robust activation. 
We quantified the effect of this thermal dose on microbial cell 
viability and simultaneously tested a pulsatile heating scheme that 
was previously shown to enhance viability in mammalian cells35. 
For the pulsatile heating scheme, the duty cycle was kept constant 
at 50% while alternating the temperature between 37 °C and 42 
°C, resulting in a total of one hour at 42 °C over a two-hour 
period, with pulse duration varying between 1 and 60 minutes 
(Fig. 1e). As hypothesized, cell viability decreased as the pulse 
duration increased, while induction levels did not significantly vary 
(Fig. 1f). Based on these results, we selected a five-minute pulse 
duration for subsequent applications, as this heating paradigm 
enhanced cell viability while being readily achievable with a 
focused ultrasound setup. Collectively, our experiments identified 
and characterized TcI42 as an effective thermal transducer to 
control gene expression in the therapeutically relevant EcN strain. 
 
Constructing a thermally actuated state switch. On its 
own, the TcI42 switch is not sufficient for microbial cancer 
therapy. This switch is transiently activated for the duration of 
heating, while tumor therapy requires weeks to effectively suppress 
tumor growth. Since daily FUS application over this period is 
infeasible in a clinical setting, we set out to engineer a gene circuit 
that maintains a prolonged therapeutic response following a single, 
brief thermal activation. 
 To enable stable thermal switching, we placed the 
expression of Bxb1, a serine integrase, under the control of a 
thermally inducible promoter regulated by TcI42 (Fig. 2a). Our 
design combines the temperature sensitivity of TcI42 with the 
permanent effector function of the Bxb1 integrase. At 
physiological temperatures of approximately 37 °C, constitutively 
expressed TcI42 represses the expression of Bxb1. Upon thermal 
stimulation, the release of TcI42 repression results in a burst of 
Bxb1 expression. Thermally derepressed Bxb1 expression 
catalyzes the inversion and activation of a P7 promoter that is 
responsible for driving the expression of a fluorescent reporter to 
monitor the state of the circuit and a tetracycline resistance cassette 
serving as a placeholder for a therapeutic protein (Fig. 2a). 
Because the DNA inversion event that activates P7 is permanent, 
this promoter will continue to drive the expression of its protein 
payloads even when the temperature stimulus is terminated. To 
avoid unregulated expression of Bxb1 we insulated the activity of 
the temperature-activated promoter by inserting two strong 
terminators upstream to block activity from other regions of the 
plasmid36. 
 The ideal performance of the circuit described above 
would maintain low baseline activity at physiological temperature 
while providing strong and lasting induction once thermally 
stimulated. To achieve this performance, we tuned three key 
sequence elements affecting Bxb1 translation and stability: the 
Bxb1 ribosomal binding sequence (RBS), start codon, and ssrA 
degradation tag (Fig. 2b). To efficiently identify the best versions 
of these elements we performed a library screen that consisted of 
randomized 6-bp sequences within the Bxb1 RBS, two Bxb1 start 
codon choices, and randomized terminal tripeptides in the Bxb1 
ssrA degradation tag37. Two start codons were tested because the 
non-canonical start codon GUG can down-regulate ribosomal 
efficiency, and the last three amino acids of the ssrA degradation 
tag were randomized because they strongly modulate the 
degradation rate of ssrA-tagged proteins38. A total landscape of 
approximately 107 possible unique variants was sampled using a 
high-throughput plate-replication assay (Fig. 2b). Agar plates 
containing colonies of library members were first replicated, and 
then one plate was incubated at 37 °C to assess baseline 
expression, while the other plate was stimulated at 42 °C for an 
hour and returned 37 °C for the rest of the growth period. The 
temperature-dependent fluorescence of a representative sampling 
of variants is shown in Figure 2c. We selected a subset of variants 
with low leak and high activation to quantify their switching 
performance with a larger number of replicates (Fig. 2d). Out of 
these candidates, we selected candidate #5 for further 
optimization since it activated the largest percentage of the cells 
upon stimulation, a metric that is important to ensure strong 
therapeutic activity in vivo, while still retaining a reasonable 
temperature-dependent fold change (Fig. 2d).  
 To reduce the baseline activity of candidate #5, we 
modified two additional circuit components (Fig. 2e). The first 
modification changed the origin of replication from the low-copy 
origin pSC101 to the medium-copy origin p15A. The second 
modification explored the effect of inserting a temperature-
sensitive terminator upstream of the Bxb1 coding sequence. This 
terminator introduces a temperature-sensitive secondary structure 
in the mRNA transcript that helps terminate protein expression at 
low temperatures, adding to the control provided by TcI42 to 
prevent leaky Bxb1 protein production at physiological 
temperature39. At 42 °C, this terminator loses its secondary 
structure and Bxb1 expression is unimpeded. We assessed the 
performance of four constructs with either one or both of these 
modifications (Fig. 2f). Increasing the copy number of the plasmid 
and inserting the terminator reduced baseline activation 
independently. When combined together, these modifications 
resulted in significantly reduced leakage while maintaining a large 
fold-change in activated cells upon induction. The resulting 
construct, obtained through a combination of randomized and 
rational engineering, displayed a more than 100-fold change in 
activity between 37 °C and 42 °C. 
 
Engineering cells for thermally actuated secretion of 
anticancer immunotherapy. To demonstrate that engineered 
cells containing our optimized thermally actuated circuit can 
function in a clinically relevant scenario, we modified the output 
of the circuit to express a therapeutic payload (Fig. 3a).  In 
particular, we selected αCTLA-4 and αPD-L1 nanobodies, which 
block signaling through the CTLA-4 and PD-L1 checkpoint 
receptor pathways, that are heavily implicated in T-cell silencing 
within immunosuppressive solid tumors. Checkpoint inhibitors 
such as αCTLA-4 and αPD-L1 have emerged as a major class of 
cancer therapy, but their therapeutic efficacy is commonly 
accompanied by the risk of unintentionally activating 
autoimmunity in bystander tissues when administered 
systemically40,41. By combining the ability of FUS to target specific 
areas deep within tissues with a highly specific thermal switch, we 
reasoned that we could target the activity of these potent 
immunomodulators to tumors and thereby mitigate the risk of 
systemic exposure.  
αCTLA-4 and αPD-L1 have been shown to produce 
antitumor effects when released by tumor-injected probiotics10. 
We hypothesized that local release of these proteins in tumors by 
FUS-activated systemically administered bacteria would supress 
tumor growth. To test this hypothesis, we fused αCTLA-4 and 
αPD-L1 to a PelB secretion tag to enhance their secretion upon  
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activation and cloned each construct in place of the tetracycline 
cassette in our optimized switching circuit. In addition, to stabilize 
our plasmids for long-term retention in vivo without antibiotic 
selection, we added an Axe-Txe toxin-antitoxin stability domain,  
which ensures retention of the plasmid in a cell population by 
eliminating cells that lose it42,43. 
The thermal switching functionality of our therapeutic 
circuits closely resembled their non-therapeutic counterpart. The 
 
Figure 2 | Construction and optimization of a temperature responsive state switch. (a) Illustration of the genetic circuit constructed to 
establish a temperature responsive state switch. TetR is the tetracycline resistance cassette. (b) Illustration of the sites targeted in a high throughput 
screen to optimize circuit switching. A representative fluorescence image of replica plates used to screen for circuit variants. Plates were incubated at the 
indicated temperature for one hour and further incubated at 37 °C until colonies grew large enough for analysis. The orange circle indicates an example 
colony selected for further assay. (c) Circuit variants from the screen in b characterized for their fluorescence at 37 °C and 42 °C. (d) Percent conversion 
to the on-state 24 hours after a 1-hour thermal stimulation at 42 °C or 37 °C for five of the circuit variants from (c). (e) Summary of rational modifications 
made to reduce leakage in the circuit at 37 °C. (f) Percent induction 24 hours after a 1-hour of thermal induction at 42 °C compared to baseline 
incubation at 37 °C for four circuit variants described in e. Error bars represent ± SEM. N=4 biological replicates for each sample. 
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circuit containing αCTLA-4 maintained a tight off-state at 37 °C 
while exhibiting robust fold-changes upon induction at 42 °C and 
43 °C (Fig. 3b). The 43 °C condition was added to allow for 
comparison with in vivo experiments, where this slightly higher 
temperature is targeted as the focal maximum inside the tumor to 
allow more of the mass to be heated above 42 °C. 
To assess the secretion of therapeutic nanobodies upon 
activation, we stimulated the cells for one hour at 37 °C, 42 °C 
and 43 °C, then cultured them for one day at 37 °C, and 
performed a Western Blot to evaluate the levels of αCTLA-4 
nanobodies released in their media. This experiment 
demonstrated that αCTLA-4 nanobodies are reliably secreted 
exclusively upon stimulation at 42 °C and 43 °C (Fig. 3c). We 
could not detect any secretion when the cells were incubated at 37 
°C. Similar characterization was performed for cells expressing 
αPD-L1. 
  
Activation of engineered microbes with focused 
ultrasound elicits in vivo tumor suppression. To enable 
thermal control of engineered therapeutic microbes in vivo we built 
a FUS stimulation setup capable of locally delivering an activation 
signal within tumors. An ideal setup should be able to elevate the 
local temperature within a tumor to a predetermined level and 
autonomously cycle between that temperature and 37 °C every 
five minutes to enact our optimized pulsatile heating scheme. In 
our FUS hyperthermia system (Fig. 4a), a holder secured an 
anesthetized tumor-bearing mouse vertically in a degassed water 
chamber. The chamber also held a submerged feedback-
controlled ultrasound transducer that used the temperature of the 
tumor to adjust its output intensity in real time to achieve the target 
temperature. We demonstrated that this system is capable of 
toggling the temperature in the tumor of a living animal between 
37 °C and 43 °C every five minutes (Fig. 4a). We set the focal 
maximum temperature inside the tumor at 43 °C to allow more of 
the mass to be heated above 42 °C and ensure reliable activation 
within the context of a mouse. While this could lead to some 
thermal damage, we reasoned that such damage within the tumor 
is acceptable and could help enhance the microbial therapy44,45. 
Using this in vivo setup, we tested our ability to locally 
activate systemically administered therapeutic microbes inside 
tumors. We seeded 5x106 A20 murine tumor cells in the right 
flanks of BALB/c mice (Fig. 4b). Once the tumors grew to 
approximately 100 mm3, we intravenously injected 108 EcN cells 
comprising a 1:1 mixture of cells engineered for thermally-
actuated αCTLA-4 or αPD-L1 secretion. Injected microbes were 
given two days to engraft in tumors before they were stimulated  
with FUS. After FUS activation, tumor growth was monitored to 
assess therapeutic efficacy.  
We observed major retardation in tumor growth in FUS-
treated tumors colonized by therapeutic cells, while growth rates 
in controls including non-FUS treated mice, animals treated with 
only FUS, and subjects injected with wild-type EcN were 
substantially higher (Fig. 4c). After completing this experiment, 
we collected the tumors, chemically homogenized them, and 
plated the suspension on selective media. By counting the 
percentage of activated bacteria, we demonstrated that our 
thermal switch is exclusively activated in targeted tumors and 
remains active up to at least two weeks post activation (Fig. 4d). 
One of the six FUS-activated tumors disappeared as a result of the 
treatment and bacterial activation inside it could not be quantified. 
In two out of six FUS-treated tumors, ultrasound failed to activate 
the therapeutic bacterial circuit. This could be due to limitations 
in our heating setup, which is currently capable of only partially 
heating the tumor mass. The two non-activated mice were 
removed from our analysis of tumor growth. Overall, our in vivo 
experiments demonstrated that EcN cells engineered for thermally 
controlled checkpoint inhibition could home to and engraft in 
tumors from systemic circulation, become activated specifically in 
response to FUS, maintain this activity for at least two weeks after 
a 1-hour FUS treatment and significantly reduce tumor growth. 
 
 
Figure 3 | Thermally activated sustained release of immunotherapeutic payload. (a) Temperature responsive state switch modified to 
release αCTLA-4 or αPD-L1 nanobodies. The circuit includes an Axe-Txe stability cassette. (b) Percent activation 24 hours after a 1-hour of thermal 
induction at 37 °C, 42 °C or 43 °C for the circuit described in a. (c) Western blot against hexahistidine-tagged αCTLA-4 nanobodies. Cells were 
induced for 1 hour at 37 °C, 42 °C or 43 °C, then expanded in 5 ml of media for 24 hours at 37 °C before collecting the media and assaying for the 
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DISCUSSION 
Our results establish a cell-based system for targeted 
immunotherapy that couples the special ability of therapeutic 
bacteria to home into the necrotic core of solid tumors with the 
capacity of FUS to locally activate their therapeutic function. The 
sustained activation of these therapeutic bacteria is enabled by a 
thermal state switch developed through high throughput genetic 
engineering to have low baseline activity, rapid induction upon 
stimulation and sustained activity in situ. When this state switch is 
used to actuate the release of immune checkpoint inhibitors, the 
resulting engineered microbes can be activated inside tumors by 
brief FUS exposure to secrete their therapeutic payload over an 
extended timeframe and substantially reduce tumor growth. 
 The growing body of work on bacteria-based therapies46–
49 and the increasing clinical acceptance of FUS50,51 provide FUS-
actuated bacterial therapeutics a path to ultimate clinical 
implementation. Potential disease targets include cancers with 
readily identified primary masses that are challenging to resect 
surgically, such as head-and-neck, ovarian, pancreatic or brain 
tumors. FUS-actuated bacterial therapeutics could be also relevant 
to metastatic tumors since microbial therapy in a single tumor 
mass can generate a strong systemic adaptive immune response, 
and eliminate distant tumor lesions through a potent abscopal 
effect52. However, further work will be needed to optimize the 
timing, dose and molecular identity of FUS-activated therapy 
release for each application. To enhance therapeutic efficacy, it 
may be beneficial to combine FUS-activated bacterial therapeutics 
with other molecular or cellular therapies. For example, 
engineered bacteria and immune cells have distinct and often 
complementary tumor entry and engraftment profiles. 
Engineering microbes that successfully enter immunosuppressed 
tumor regions to secrete checkpoint inhibitors or cytokines could 
help make this environment more accessible to engineered T cells. 
In this way, the bacteria and T cells can synergistically exert their 
 
Figure 4 | Ultrasound-activated bacterial immunotherapy reduces tumor growth in vivo. (a) Illustration of the automated setup used 
to deliver FUS hyperthermia to tumors (left) and representative time course of tumor temperature from a mouse treated with alternating 5-min steps 
between 37 °C and 43 °C. (b) Diagram illustrating the experiment performed to assess the activation of microbial antitumor immunotherapy in vivo. 
Mice were injected with a 1:1 mixture of EcN cells carrying the αCTLA-4 or αPD-L1 circuits, or wildtype EcN. EcN cells were washed and adjusted 
to 0.625 OD600 before injecting 100 µL per mouse intravenously. Ultrasound was applied for a total of 1 hour at 43ºC with 50% duty cycle and 5-min 
pulse duration. (c) Tumor sizes measured over two weeks in mice treated with wildtype EcN, therapeutic microbes in the absence of FUS, therapeutic 
microbes and FUS treatment, or FUS treatment alone. (d) Percent activation of therapeutic EcN isolated from FUS-treated and non-FUS-treated 
tumors two weeks after FUS treatment. One of the FUS-activated tumors disappeared after treatment and bacterial activation inside it could not be 
quantified. Where not seen, error bars (±SEM) are smaller than the symbol. At least five mice were used for each control condition. 
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therapeutic function from the inside-out and from the outside-in, 
respectively. Beyond tumor therapy, locally activated bacterial 
agents have potential utility in a wide array of other biomedical 
applications. For example, FUS-controlled state switches could be 
useful in controlling the activity of gut microbes in vivo53, the 
function of cell-based living materials in vitro54–57, and in industrial 
metabolic engineering24,58. 
 
MATERIALS AND METHODS 
 
Plasmid Construction and Molecular Biology 
All plasmids were designed using SnapGene (GSL Biotech) and 
assembled via reagents from New England Biolabs for KLD 
mutagenesis (E0554S) or Gibson Assembly (E2621L). After 
assembly, constructs were transformed into NEB Turbo (C2984I) 
and NEB Stable (C3040I) E. coli for growth and plasmid 
preparation. The Bxb1 recombinase-encoding gene was a kind gift 
of Richard Murray (Caltech). Integrated DNA Technologies 
synthesized other genes and all PCR primers. Plasmids containing 
the αCTLA-4, αPD-L1, and Axe-Txe genes were kind gifts from 
of Tal Danino (Columbia University). 
 
Preparation of cell lines for in vitro and in vivo experiments 
Plasmids containing engineered genetic circuits were transformed 
into Nissle 1917 E. coli (Mutaflor®). Nissle cells were cultured in 
LB broth (Sigma) and grown on LB agar plates (Sigma) containing 
appropriate antibiotics. Singular colonies were picked into LB 
broth and grown overnight in a shaking incubator (30 °C, 250 
rpm). The next day, optical density measurements (OD600) were 
taken, and the saturated cultures were diluted to 0.1 OD600. 
Diluted cultures were then allowed to grow to exponential phase 
until they reached 0.6 OD600 before starting assays. Optical density 
measurements were taken using a Nanodrop 2000c (Thermo 
Scientific) in cuvette mode.  
 
Western Blot 
Five milliliters of cell media were collected for each sample and 
concentrated with an Amicon® Ultra-15 Centrifugal Filter Unit. 
Concentrated cell media was then mixed with Laemmli loading 
buffer and BME before loading into a pre-cast polyacrylamide gels 
SDS-PAGE gel (Bio Rad) and ran at 75 V for 140 minutes. 
Western blotting was performed using the Transblot Turbo 
apparatus and nitrocellulose membrane kit (Bio Rad). Transfer 
was performed at 25 V for 7 minutes. Membranes were blocked 
with 5% Blotto milk (Santa Cruz Biotechnology) in 0.05% TBS-
Tween for 1 hour at room temperature. Primary staining was 
performed using the mouse anti-His sc-8036 antibody (Santa Cruz 
Biotech) overnight at 4 °C. Blots were then washed three times for 
15 minutes at 4 °C with 0.05% TBS-Tween and stained for 4 
hours with mouse IgG kappa binding protein (m-IgGκ BP) 
conjugated to Horseradish Peroxidase (HRP) (Santa Cruz Biotech, 
sc-516102) at room temperature. After three 15-minute washes, 
HRP visualization was performed using Super signal west Pico 
PLUS reagent (Thermo Fisher Scientific). Imaging was performed 
in a Bio-Rad ChemiDoc MP gel imager. A subsequent epi white 
light image of the blot under the same magnification was acquired 
to visualize the stained molecular weight standards. 
 
Thermal regulation assay 
Once bacterial cell cultures reached approximately 0.6 OD600, 50 
µL aliquots of each sample was transferred into individual Bio-Rad 
PCR strips with optically transparent caps and subsequently 
heated in conditions specific to the experiment using a Bio-Rad 
C100 Touch thermocycler with the lid set to 50 °C. Following 
heating, cells continued to incubate overnight undisturbed at 
either 30 °C (Figure 1) or 37 °C (Figure 2-4). The PCR strips were 
then removed, vortexed, and spun down, and the green 
fluorescence of each of the samples was measured using the 
Strategene MX3005p qPCR (Agilent) and an unamplified FAM 
filter. To measure cell density, the samples were diluted 1:4 with 
fresh LB media (without antibiotic) and then transferred into 
individual wells of a 96-well plate (Costar black/clear bottom). 
Optical density measurements were taken using the SpectraMax 
M5 plate reader (Molecular Devices). In order to quantify the 
temperature-dependent gene expression (𝐸) using background-
subtracted, OD-normalized fluorescence (Fig. 1b-d, 1f, 2c), 





In this equation, we define 𝐹 as the raw fluorescence measurement 
and 𝑂𝐷 is the OD600 measurement of the sample. The value of the 
blank fluorescence and blank optical density was determined as the 
average of N = 4 samples of untransformed Nissle cells, as opposed 
to engineered Nissle cells, in LB. 
 
Screens to optimize circuit behavior 
To improve Bxb1 thermal regulation, a sequence randomized 
library of the RBS, start codon, and ssrA degradation tag was 
ordered from Integrated DNA Technologies. PCR products that 
included the Bxb1 coding region and immediately surrounding 
sequences were amplified using custom primers and were inserted 
into the backbone of the rest of the parent plasmid using Gibson 
Assembly (Fig. 2b-d). This library was transformed into EcN and 
plated on LB Agar plates with antibiotic resistance at a low colony 
density of approximately 30 colonies per petri dish. Following 
overnight incubation at 30 °C to allow the colonies to become 
visible, these plates were then replicated into two daughter petri 
dishes using a replica-plating tool (VWR 25395-380). The parent 
petri dish was incubated at 4 °C until the conclusion of the 
experiment. One daughter plate was grown overnight at the 
baseline temperature of 37 °C, and the other was incubated at 42 
°C for 1 hour and then moved to 37 °C overnight. After colonies 
became visible, the plates were imaged using a 530/28 nm 
emission filter to determine colonies that were fluorescent at the 
‘on’ temperature but opaque at the ‘off’ temperature (Bio-Rad 
ChemiDoc MP imager). Promising library variants were then 
picked from the corresponding parent petri dish at 4 °C and 
analysed against the parent plasmid of the library using the liquid 
culture fluorescence-based assay described above. 
 
Percent switching assay 
Strips of liquid bacteria samples were prepared and incubated in 
the Bio-Rad Touch thermocycler. After the prescribed thermal 
stimulus and incubation at 37 °C, PCR strips were removed, 
vortexed, and spun down on a tabletop centrifuge. Five 1:10 serial 
dilutions in liquid LB were then performed, transferring 10 µL of 
sample into 90 µL of LB media sequentially. After thorough 
mixing, 50 µL of the most diluted samples was plated onto an LB 
plate and allowed to incubate at 30 °C overnight. Upon the 
appearance of visible colonies, plates were imaged using the same 
Bio-Rad ChemiDoc MP imager with both blue epifluorescence 
illumination and the 530/28 nm emission filters. The percentage 
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All animal procedures were performed under a protocol approved 
by the California Institute of Technology Institutional Animal 
Care and Use Committee (IACUC). 8-12 week-old BALB/c 
female mice were purchased from Jackson Laboratory. To 
establish A20 tumor models in mice, 5 × 10* A20 cells were 
collected and suspended in 100 µL phosphate buffer saline (PBS) 
prior to subcutaneous injection into the flank of each mouse. When 
tumor volumes reached approximately 100 mm3, engineered EcN 
cells prepared according to the procedure outlined in the section 
above were then collected by centrifugation (3000 g for 5 min), 
washed with phosphate buffer saline PBS 3 times, and diluted in 
PBS to 0.625 OD600. 100 µL of the resulting solution was injected 
into each of the A20 tumor bearing mice via tail vein. For thermal 
actuation using ultrasound, mice were anesthetized using a 2% 
isoflurane-air mixture and placed on a dedicated animal holder. 
Anesthesia was maintained over the course of the ultrasound 
procedure using 1-1.5% isoflurane, adjusted in real-time to 
maintain the respiration rate at 20-30 breaths per minute. Body 
temperature was continuously monitored using a fiber optic rectal 
thermometer (Neoptix). When appropriate, the target flank was 
thermally activated using the automated FUS setup described 
below, cycling between the temperatures of 43 °C and 37 °C every 
5 minutes for 1 hour of total heating. Following ultrasound 
treatment, the mouse was returned to its cage and the size of its 
tumor was measured with a caliper to track the therapeutic 
efficacy. When the tumors reached ~1000 mm3 mice were culled 
and the tumors were collected for analysis. Mice that did not have 
microbial cells in their tumors were excluded from the study. 
  
Tumor analysis 
Tumors were collected and homogenized in ten milliliters of PBS 
containing 2 mg/ml collagenase and 0.1 mg/ml DNAse for one 
hour at 37 °C. Homogenized tumors were serially diluted and 
plated onto LB plates to quantify the number of cells colonizing 
the tumors. The percentage of cells activated within tumors was 
determined by counting the number of GFP positive cells. 
 
Feedback-controlled focused ultrasound   
We developed a closed loop thermal control setup to maintain a 
specified predetermined temperature within the tumor of a mouse 
by modulating the intensity of the FUS. This setup includes a 
water bath filled with pure distilled water that is being actively 
cleaned and degassed with an AQUAS‐10 water conditioner 
(ONDA) and maintained at 33 °C with a sous vide immersion 
cooker (InstantPot Accu Slim). A tumor-bearing mouse that has 
been anesthetized as described above is fastened nose up vertically 
to an acrylic arm that is connected to a manual 3D positioning 
system (Thorlabs) to enable 3D motion of the mouse within the 
water bath. A Velmex BiSlide motorized positioning system is used 
to submerge and position the 0.67 MHz FUS transducer (Precision 
Acoustics PA717) such that the focal point of the transducer lies 
within the tumor of the mouse. A signal generator (B&K #4054B) 
generates the thermal ultrasound signal which is then amplified 
(AR #100A250B) and sent to drive the ultrasound transducer. The 
water in this chamber acts as the coupling medium to transfer the 
ultrasound wave from the transducer to the tumor. To measure 
the internal tumor temperature during a heating session we 
temporarily implant a thin fiber optic temperature probe (Neoptix) 
into the tumors. This temperature readout is also used to align the 
focus of the transducer with the tumor by emitting a constant test 
thermal ultrasound signal. Once the system is aligned, we run a 
Matlab closed loop thermal control script that regulates the signal 
generator output. Feedback for the controller is provided by the 
temperature measurements acquired with a sampling rate of 4 Hz. 
The actuator for the controller is the voltage amplitude of the 
continuous sinusoidal signal at 0.67 MHz used to drive the FUS 
transducer, where the voltage is adjusted also at 4 Hz.  The system 
uses a PID controller with anti-windup control that modifies the 
amplitude of the thermal ultrasound waveform to achieve a 
desired temperature in the targeted tissues. The Kp, Ki, Kd, and 
Kt parameters for the PID and anti-windup were tuned using 
Ziegler-Nichols method, and in some cases adjusted further 
through trial-and-error tuning to achieve effective thermal control. 
 
Statistics and replicates 
Data is plotted and reported in the text as the mean ± S.E.M. 
Sample size is N = 4 biological replicates in all in vitro experiments 
unless otherwise stated. This sample size was chosen based on 
preliminary experiments indicating that it would be sufficient to 
detect significant differences in mean values. P values were 
calculated using a two-tailed unpaired t-test. 
 
Data and code availability 
Plasmids will be made available through Addgene upon 
publication. All other materials and data are available from the 
corresponding author upon reasonable request. 
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